PCSK9 inhibitor and atorvastatin reduce cardiac impairment in ovariectomized prediabetic rats via improved mitochondrial function and Ca(2+) regulation

Post‐menopausal women have a higher risk of developing cardiometabolic dysfunction. Atorvastatin attenuates dyslipidaemia and cardiac dysfunction but it can have undesirable effects including increased risk of diabetes and myalgia. Currently, the proprotein convertase subtilisin/kexin type 9 (PCSK9)...

Descripción completa

Detalles Bibliográficos
Autores principales: Amput, Patchareeya, Palee, Siripong, Arunsak, Busarin, Pratchayasakul, Wasana, Thonusin, Chanisa, Kerdphoo, Sasiwan, Jaiwongkam, Thidarat, Chattipakorn, Siriporn C., Chattipakorn, Nipon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417720/
https://www.ncbi.nlm.nih.gov/pubmed/32628813
http://dx.doi.org/10.1111/jcmm.15556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417720/
https://www.ncbi.nlm.nih.gov/pubmed/32628813
http://dx.doi.org/10.1111/jcmm.15556

Ejemplares similares